Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

The term heparin resistance (HR) is used by clinicians without specific criteria. We performed a literature search and surveyed our SSC membership to better define the term when applied to medical and intensive care unit patients. The most common heparin dosing strategy reported in the literature (53%) and by survey respondents (80.4%) was the use of weight-based dosing. Heparin monitoring results were similar based on the proportion of publications and respondents that reported the use of anti-Xa and activated partial thromboplastin time. The most common literature definition of HR was >35 000 U/d, but no consensus was reported among survey respondents regarding weight-based and the total dose of heparin when determining resistance. Respondent consensus on treating HR included antithrombin supplementation, direct thrombin inhibitors, or administering more heparin as the strategies available for treating HR. A range of definitions for HR exist. Given the common use of heparin weight-based dosing, future publications employing the term HR should include weight-based definitions, monitoring assay, and target level used. Further work is needed to develop a consensus for defining HR.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtha.2023.08.013DOI Listing

Publication Analysis

Top Keywords

heparin resistance
8
common heparin
8
survey respondents
8
weight-based dosing
8
heparin
6
defining heparin
4
resistance communication
4
communication isth
4
isth ssc
4
ssc subcommittee
4

Similar Publications

Thromboelastographic assessment of hypofibrinolysis in stored plasma samples: A novel spike-in method.

Thromb Res

August 2025

Institute for Clinical and Experimental Transfusion Medicine, Tuebingen, Germany; Center for Clinical Transfusion Medicine, University Hospital of Tuebingen, Tuebingen, Germany.

Introduction: Congenital or acquired dysregulation of fibrinolytic system can lead to bleeding (hyperfibrinolysis) or thrombosis (hypofibrinolysis), with increased risk for multi-organ failure. Standard clotting-based assays provide limited insight into fibrinolytic status. In contrast, thromboelastography (TEG), a whole blood assay, offers a comprehensive assessment of the coagulation and fibrinolytic systems.

View Article and Find Full Text PDF

The use of enoxaparin is generally not recommended in patients with end-stage renal disease (ESRD) and undergoing haemodialysis. We describe the administration of high-dose enoxaparin in a haemodialysis patient with heparin resistance and recurrent deep vein thrombosis (DVT) outlining a novel dosing regimen along an innovative method for monitoring antifactor Xa activity. As a last resort of his recurrent DVT, a critically ill intensive care unit patient undergoing dialysis was prescribed high-dose enoxaparin, administered exclusively after dialysis, on dialysis days for a period of 2 months.

View Article and Find Full Text PDF

This research introduces carboxymethyl kappa-carrageenan-chitosan polyelectrolyte multilayers as a promising and sustainable alternative to heparin, used in surface treatments for blood-contacting medical devices. The polysaccharide-based surface coatings have good cytocompatibility and resist microbial adhesion of both Pseudomonas aeruginosa and Staphylococcus aureus. The blood compatibility of surfaces containing carboxymethyl-kappa-carrageenan was directly compared to similar polyelectrolyte multilayers containing heparin.

View Article and Find Full Text PDF

Pancreatic ductal adenocarcinoma (PDAC) stands to become the second most deadly cancer by 2030. The small GTPase, KRAS, is mutated in over 90% of PDAC patients and considered the primary driver mutation. Despite being an almost ubiquitous event, KRAS mutations have been difficult to target therapeutically, particularly KRAS , the most common mutation in PDAC.

View Article and Find Full Text PDF